Alembic Limited, with an established presence in the Indian pharma industry has a proud, historical track record going back one hundred years. With a turnover in excess of Rs1000 crores today, Alembic Limited is one of India’s leading integrated pharmaceutical companies. We continue to enjoy leadership positions in antibiotics, anti-infective, anti-cough and also have significant worldwide presence in specialty therapeutic areas such as cardiology, neurology, diabetology, etc. We have also plans for expansion in Ophthalmic etc.

Alembic’s manufacturing facilities are at Vadodara, Panelav in Gujarat, and Baddi in Himachal Pradesh. The facilities are approved by the US FDA, EDQM, TGA, MHRA, and MCC.

Alembic Research Center (ARC) a world-class research organization provides a comprehensive range of services in the areas of synthetic chemistry, formulations, NDDS, as also preclinical pharmacology, bioequivalence / bioanalytical studies, etc. ARC, designed to state-of-the-art GLP standards, is spread over an area of 120,000 sq ft, manned by over 300 scientists working on latest technology and systems.

Our current employee strength is in excess of 4500 across the country. A continuously expanding organization, we invite dynamic, result-oriented professionals to join us across various functions

Designation Marketing Executive

Job Description Face of the company for customers. Implement

Company strategy. Implement of product promotion strategy. Generate prescriptions in line with the business strategy. Maintain and develop relations with existing and new customers through appropriate propositions and sales methods. Optimize quality of service, business growth, and customer satisfaction.

Desired Profile

Freshers with Qualification - BSc / MSc / BPharm . 

Age - Upto 25 years ( For Freshers )

       - Upto 27 years ( For candidates having minimum 1 year

         of Medical Representative Experience )

Experience 1 - 2 Years

Industry Type Pharma/ Biotech/Clinical Research

Role Medical Rep.

Functional Area

Sales, BD

Education UG - B.Pharma - Pharmacy,B.Sc - Any Specialization,BVSC - Veterinary Science PG - Any PG Course - Any Specialization

Compensation:

Best in the Industry

Location Jamshedpur, Ranchi, Silchar,Motihari Saharsha , Sahebganj

Keywords Medical Repsentative

Contact Mr. Anupam Roy - ZSM - East Alembic Ltd

Telephone 09339143789

Website http://www.alembic-india.com

Job Posted 10 Dec

Reference Mail to mx.tapash.dey@alembic.co.in; mx.anupam.roy@alembic.co.in

.: DOMESTIC FORMULATIONS

Our extensive range of Finished Dosage Forms cover every aspect of human life. We possess expertise in the manufacture of high volume Finished Dosage Forms and effectively control their release profile. This expertise is in the field of sterile as well as non-sterile dosage forms. Alembic has commissioned a solid Oral dosage facility approved by MCC South Africa and MHRA UK

Find out more about :

 

Branded Formulations

Antibiotics & Anti bacterials Cough & Cold

Antihistamines NSAIDS

Oral Hypoglycemic Herbals & Nutraceuticals

Cardiovascular Others

 

For Business Inquiries please click here

 

Generics

At present we have 90 brands with extension in various forms covering the therapeutic segments of Antibiotic, Cough & cold, NSAID, B-complex, C.V.Drugs etc.

 

Therapeutic segments Antiallergic

Anticold Preparation Anthelminitic

Antimalarials Antimicrobials

Antioxidants Antipyretics

Antiseptic Antispasmodic

Antiulcerants Cardiovascular Drugs

Corticosteroids Cough Preparations

Enzyme Preparation Mucolytics & Proteolytics

Nsaids Tranquiliser

Vitamin Preparations Others .: BRANDED FORMULATIONS - GYNAECOLOGICAL  

For Business Inquiries please click here   

Antibiotics & Antibacterials Herbals & Nutraceuticals

Cough & Cold Cardiovascular

Antihistamines GynaecologicalNSAIDS Gastrointestial

Oral Hypoglycemic Ophthalmic PreparationsOthers

GYNAECOLOGICAL PRODUCTS

Crina 20

Ethinyl Estradiol 20 mcg & Drospirenone 3 mg

Bottle 20 Tabs

CYCLOSET

Tranexamic acid 500 mg + Mefenamic acid 250 mg tab

Strip 6 Tabs

FOLINAL

Folic Acid 5 mg Bottle 30 Tabs

FOLINAL PLUS

Folic Acid 5 mg + Methylcobalamin 750 mcg + Pyridoxine 10 mg

Strip 10 Tabs

FOLIRIPE

Letrozole 2.5 mg tab    

GESTOFIT

Natural Micronised Progesterone Strips 10 Tabs

Natural Micronised Progesteron Injection 2ml/4ml

HARMONI    

Cyperoterone Acetate 2 mg + Ethinyl estradiol 0.035 mg tab

Strips 21 tabs

LACTONIC    

Satavari (15 gm/100gm), Sowa, Palak, Safed Jeera

Bottle 200 gms

MEGA MOM    

Whey Protein Isolate with DHA 80 mg & GLA 25 mg per 100 gm

Bottle 200 gms

OVIGYN    

HCG 2000, 5000, 10000 IU Bottle 200 gms

RICHAR-XT    

Ferrous Ascorbate 100 mg + Folic Acid 1.5 mg tab

strips 10 gms

RICHAR-XT - Injection    

Iron Sucrose 100 mg/5 ml Injection 5 ml

Vehycal    

Calcium Aspartate anhydrous 560 mg tab equivalent to 73 mg elemental calcium

Strips 10 Tabs

     

  BUSINESS OPPORTUNITIES  We are always looking for collaborative business opportunities in the areas of Marketing, Distribution,Co-development, Research, Contract Manufacturing & Joint Ventures. If you are interested in exploring possibilities in any of these areas please click on appropriate partner areas to send us your query. 

 

Name *

Designation *

Company *

Mailing Address *

City *

Zip/Postal Code *

Country *

Telephone *

Fax

E-mail address *

Website

 

What kind of Business Partnership are you looking for? (Please check the appropriate box)

Marketing DistributionCo-development

Research

Contract Manufacturing

Joint VentureOther enquiries

   

 

WELCOME TO ARCNews & Events

ARC is a rapidly growing contract research services organization providing a wide range of services to global research based pharmaceutical and biotech companies.

The services provided are in the domains of Chemistry, Formulations, Pre-clinical Bioequivalence / Bioanalytical studies.  

ARC has a multidisciplinary team based approach to the various challenges posed by the drug discovery industry.

We trust in integrity, confidentiality and quality of our research solutions and can be a valued partner

to your Research team and drug discovery process.

ARC PROFILE

Based at Vadodara, India (250 miles north of Mumbai) ARC is the research and development division of Alembic Limited, one of India's reputed and well-established integrated-pharma company.

Objective:

ARC

Offers value-added solutions to increase the efficiency of global pharmaceutical and biotech companies’ R&D efforts.

Through partnering complements the intense R&D efforts of these companies’ to discover, develop & manufacture quality products with greater speed, at reduced costs and total confidentiality.

 Since its inception in the year 2003, ARC has gained a reputation of a well-known contract research organization providing good-quality and wide range of services.

Today, we can boast of a number of reputed global companies on our list of clients collaborating with us in the various domains of services we offer..

With a state-of-the-art research infrastructure spread over an area of 120,000 square feet, ARC’s facilities have been designed according to GLP standards.

It houses all the major analytical instruments to complement the research work of its scientists. ARC has a rich-pool of scientists that bring together over 750 man-years of rich and varied experience spanning across all domains of services.

ARC ADVANTAGES

 

Since we possess the 10 commandments of Partnering…

Enviable track record

Protecting partner’s interest

Width of services

World class research infrastructure

Well-defined processes

Highly talented research team

Superior project management

Scientific advisory board

Proactive HR policies

Credible Financial & Corporate Governance Track Record

  

Enviable Track Record

ARC today has sizeable number of multi-year FTE based research contracts and projects in place with reputed MNCs. This showcases ARC’s ability to handle any complex project of MNCs, with specific reference to 

Technical competence

Infrastructure

Project management abilities and

Effective delivery through reliability, confidentiality and customer delight

  

Protecting Partner’s Interests

Protecting its partner’s interests is the primary responsibility of ARC. With India being a WTO member, we ensure total commitment and compliance to harmonized patent laws. Any product related development would be the intellectual property of our partner. Our scientists working for the clients are also bound by intellectual property confidentiality agreements.  

Width of Services

ARC offers you a wide and complete range of services ranging from Chemistry to Formulation development  and Bioequivalence studies. Our continuous efforts are to provide our clients a complete solution and act as a single point shop!  

World-class research infrastructure

ARC has all the requisite facilities for synthetic chemistry, analytical, pharmaceutical research  The laboratories are well equipped with modern equipment including NMR (300 MHz), LCMS/MS-Q trap model, HPLC, prep HPLC, flash chromatographs, GC, DSC, Chromatotron, NeoCota, Conta blender, Luminometer, Fluorimeter, UV/VIS Spectrophotometer,  Ultralow freezers etc. along with Kilo lab & pilot manufcturing plant (upto 100 Kg levels).

ARC also houses a modern information center spread over an area of 2,500 sq. ft. with a collection of over 10,000 books dedicated to pharmaceutical research. It also subscribes to over 100 international and national journals with access to Sci-finder and STN.  

Well-defined Processes

The preparation, approvals, distribution, retrieval, periodic reviews of documents is well controlled. Well-defined documentation SOPs ensure reliability and confidentiality of data generated.

ARC ensures data protection by having separate teams for clients and promoting a culture wherein confidential information does not flow across them. The reporting format is according to globally accepted or regulatory standards, aided by advanced software tools. The safety of data transmission over internet is ensured by using data encryption software.  

Highly Talented Research Team

ARC has one of the best of scientific pool (a mix of post docs & postgraduates from reputed international & national research organizations) in the Indian pharmaceutical industry. Over 750 man-years of research experience synergise drug discovery efforts.  

Superior Project Management

The project management part essentially encompasses

quote preparation & feasibility assessment, raw materials sourcing, invoicing, human resource utilization, task progress and slippage, weekly summary reporting, teleconferencing and submission of final report on project completion.

These activities are aided with use of software tools like MS-Project, SAP and ACD database.

The project manager acts as a strong interface and single point contact between its two customers viz.

External - the clients & vendorsInternal - the scientific community, management & support services.

In addition to this, regular communication between the project team with the client is facilitated using video-conferencing, teleconferencing, fax and internet.   

Scientific Advisory Board

ARC is supported by active participation of reputed scientists and technologists who are leaders in their respective fields and are committed to make ARC - a center of excellence. We already

have some well-renowned scientists on our advisory board.  

Proactive HR Policies

ARC values the intellect of its employees by encouraging continuous up-gradation of their knowledge base. ARC offers a congenial work atmosphere to foster self-motivation, self-assessment & self-confidence.

We also have a fast track recruitment process in place to cater to the changing and increasing demands of our clients in a short lead-time. We are also actively promoting scientific creativity to get access to new emerging talent, and have tied up with leading national institutes and universities in this regard.  

Credible Financial & Corporate Governance Track Record

Alembic’s past trust and credibility in Indian financial and business circles gives ARC a dependable and reliable partner image.

Thus ARC possesses the financial muscle for making investments on infrastructure, crucial to our partner’s requirements. In addition to this, Alembic’s top management is fully committed to make ARC - a world class pharmaceutical services provider organization.

ARC CHEMISTRYWithin the pharmaceutical industry, we are well known for our ability to carry out wide and safe processes for complex molecules as well as for high pressure and temperature reactions.

We provide expertise in the early stages of drug development, whether creating a synthetic route for a new chemical entity or optimizing an existing process. Our repertoire includes both classical and modern organic reactions. We also possess capabilities of impurity isolation and synthesis. The services offered under this domain are: 

Synthetic organic chemistry & creating compound libraries

Process chemistry at gm to Kg levels

Custom synthesis

Impurities isolation & synthesis

Analytical chemistry services

ARC CAREERS We share collaborative & symbiotic relationships with preferred business partners, our employees, all of whom reflect our business

ethics, trust & transparency and quality standards.

Our focus on developing human values and potential through various learning and developmental activities has groomed and retained talent internally by offering promising career opportunities.

Culture, Beliefs & Values

Relations at ARC, be it hierarchical or lateral are essentially formally informal, they are collaborative rather than being competitive. The basis of our relationship is trust.

The environment at ARC can be defined as positive, informal and not protocol oriented, built on mutual strengths, where every achievement, big or small is appreciated.

We, at ARC believe in being simple, humble, and honest. We believe in and value human dignity. We value openness and teamwork in our interpersonal dealings. We respect and reflect a mindset that is Pro Change. That is the basis of our historical existence and sustained progress.

In our quest to be a global research services provider, ARC is keen to associate with talented, high performing people. ARC prides itself for a rich talent base that can successfully propel the company to even greater heights in an increasingly competitive global R & D environment.

ARC IN NEWS

Alembic Starts Construction of new R&D center(Date: 2'nd June'03The civil work of the new R&D Centre at Vadodara, Gujarat has commenced on the 2nd of june 2003. The new Research Centre would offer state-of-the-art research infrastructure having a carpet area of 80,000 square feet.

The facility would consist of Chemistry, Analytical and Biological Laboratories. An Animal House facility for the pharmacological and toxicological studies in rodents is also being created.

The R&D Center would house an Information center subscribing to latest books, international and national journals with in-house access to Sci-finder and STThe civil work of the new R&D Centre at Vadodara, Gujarat has

commenced on the 2nd of june 2003. The new Research Centre would offer state-of-the-art research infrastructure having a carpet area of 80,000 square feet.

The facility would consist of Chemistry, Analytical and Biological Laboratories. An Animal House facility for

 Alembic, a Baroda-based pharma company, has scripted a major thrust on contract research as part of its strategy to increase its presence in the segment.Alembic has entered a contract research agreement with Chiron Corporation, a research-based pharmaceuticals company headquartered at Emeryville, California. The agreement, which has been signed between these two companies, will seek to use the expertise offered by Alembic in the field of heterocyclic chemistry. Based on Alembic's research, Chiron will develop new drugs for different therapeutic segments.

"Besides Chiron Corporation, we are also talking to a couple of foreign companies for contract research," HT Patel, senior VP, Alembic, told ET. The company seeks to boost its revenues by focusing on contract research and by utilising its R&D base, Mr Patel said.

It may be pointed out that like multinational IT companies, many foreign companies have started using the R&D base of Indian pharmaceutical companies to develop new drugs. As foreign companies have started outsourcing molecules from Indian companies, the market size of contract research is growing at a rate of 100%, a pharma analyst said. At present, market size of contract research in the country is around Rs 100 crore and as many 18 companies are engaged in contract research.

Alembic, which has core concentration on bulk drugs and formation for human health and veterinary segments, is also restructuring its business to focus on three strategic areas - nutraceuticals, antidiabetics and antibiotics - which will be the key drivers for growth in the coming years. The company has recently set up a new division for cardiovascular and diabetic drugs as well.The company is planning to launch its new drugs in these segments and is targeting the highly regulative markets like US and Europe for its new drugs.  

  Alembic enters into contract research agreement with Chiron Corp - California Source: Economic Times (Date: 5'th Nov' 02) Alembic Ltd has informed BSE that the company has entered into contract research agreement with Chiron Corporation, a Research based pharmaceutical company headquartered in Emeryville, California.

Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its flatforms in proteins, small molecules and vaccines. The multi year agreement will seek to utilize the expertise offered by company in the field of Heterocyclic chemistry.   

  Alembic and Chiron enter into a research pact Source: EconomicTimes (Date: 4'th Nov'02) Mumbai : Alembic has tied up with Chiron Corporation of the US for contract research. The multi-year deal seek to use expertise offered by the US firm in the field of heterocyclic chemistry. Chiron Corporation, applies its advanced understanding of the biology of cancer and other infectious diseases to develop products from its flatforms in proteins, small molecules and vaccines.

Alembic`s research and development team mainly targets on microbial research, reverse engineering, process improvement, new chemical entities and development of new formulations. The company has been spending around 2-3 per cent of its turnover on research and development efforts. Alembic spent around Rs 14.41 crore, or 2.31 per cent of its turnover, on R&D.

The company develops non-infringing patentable routes of manufacturing drugs, whose existing patents are set to expire in the near future. Alembic also plans to do substantial research work in the area of new chemical entities to find potent macrolides. Similar project has already been initiated in association with the National Chemicals Laboratory  

The civil work of the new R&D Centre at Vadodara, Gujarat has commenced on the 2nd of june 2003. The new Research Centre would offer state-of-the-art research infrastructure having a carpet area of 80,000 square feet.

The facility would consist of Chemistry, Analytical and Biological Laboratories. An Animal House facility for the pharmacological and toxicological studies in rodents is also being created.

The R&D Center would house an Information center subscribing to latest books, international and national journals with in-house access to Sci-finder and STN.

  ALEMBIC BETS BIG ON CONTRACT RESEARCHSource: Economic Times (Date:30'th April' 03) Alembic, a Baroda-based pharma company, has scripted a major thrust on contract research as part of its strategy to increase its presence in the segment.Alembic has entered a contract research agreement with Chiron Corporation, a research-based pharmaceuticals company headquartered at Emeryville, California. The agreement, which has been signed between these two companies, will seek to use the expertise offered by Alembic in the field of heterocyclic chemistry. Based on Alembic's research, Chiron will develop new drugs for different therapeutic segments.

"Besides Chiron Corporation, we are also talking to a couple of foreign companies for contract research," HT Patel, senior VP, Alembic, told ET. The company seeks to boost its revenues by focusing on contract research and by utilising its R&D base, Mr Patel said.

It may be pointed out that like multinational IT companies, many foreign companies have started using the R&D base of Indian pharmaceutical companies to develop new drugs. As foreign companies have started outsourcing molecules from Indian companies, the market size of contract research is growing at a rate of 100%, a pharma analyst said. At present, market size of contract research in the country is around Rs 100 crore and as many 18 companies are engaged in contract research.

Alembic, which has core concentration on bulk drugs and formation for human health and veterinary segments, is also restructuring its business to focus on three strategic areas - nutraceuticals,

antidiabetics and antibiotics - which will be the key drivers for growth in the coming years. The company has recently set up a new division for cardiovascular and diabetic drugs as well.The company is planning to launch its new drugs in these segments and is targeting the highly regulative markets like US and Europe for its new drugs.  

  

Alembic enters into contract research agreement with Chiron Corp - California Source: Economic Times (Date: 5'th Nov' 02) Alembic Ltd has informed BSE that the company has entered into contract research agreement with Chiron Corporation, a Research based pharmaceutical company headquartered in Emeryville, California.

Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop products from its flatforms in proteins, small molecules and vaccines. The multi year agreement will seek to utilize the expertise offered by company in the field of Heterocyclic chemistry.   

  Alembic and Chiron enter into a research pact Source: EconomicTimes (Date: 4'th Nov'02) Mumbai : Alembic has tied up with Chiron Corporation of the US for contract research. The multi-year deal seek to use expertise offered by the US firm in the field of heterocyclic chemistry. Chiron Corporation, applies its advanced understanding of the biology of cancer and other infectious diseases to develop products from its flatforms in proteins, small molecules and vaccines.

Alembic`s research and development team mainly targets on microbial research, reverse engineering, process improvement, new chemical entities and development of new formulations. The company has been spending around 2-3 per cent of its turnover on research and

development efforts. Alembic spent around Rs 14.41 crore, or 2.31 per cent of its turnover, on R&D.

The company develops non-infringing patentable routes of manufacturing drugs, whose existing patents are set to expire in the near future. Alembic also plans to do substantial research work in the area of new chemical entities to find potent macrolides. Similar project has already been initiated in association with the National Chemicals Laboratory   

The 101-year-old Alembic, India's oldest pharmaceutical company, has chalked out an aggressive expansion plan to double its turnover within 2 to 3 years by foraying into the regulated markets of the US and Europe as well as contract manufacturing.

The Rs 1,027-crore company has filed 13 abbreviated new drug applications (ANDAs) and 22 drug master files (DMFs) with the US Food and Drug Administration (FDA) and regulatory agencies in Europe for supply of formulations and active pharmaceutical ingredients (APIs).

Some of the ANDAs challenge innovator patents and the company's strategy will be to partner with established companies in the US and Europe for marketing formulations, said Pranav Amin, director, Alembic.

"I feel we are about ten years late to enter the regulated markets, but will file about 10-12 ANDAs every year to tap potential in the generic markets of the US and Europe. We will also tap Latin America and Africa," he said.

Alembic's plan is to follow the low-risk and less-expensive model of roping in strategic alliances with major companies with presence in the US and Europe for supplying drugs, similar to the business model of drug major Cipla, instead of creating own front-ends through greenfield projects and expensive acquisitions in various geographies.

Currently, exports to non-regulated markets contribute only 20 per cent of the turnover and plans are afoot to improve this to a ratio of 50:50 in coming years. Alembic was talking to several multinational and domestic companies to rope in alliances, he said.

"Now large retail chains in the US are looking at second-level Indian companies with quality manufacturing facilities for direct drug supplies and we will try to capitalise that opportunity. Contract manufacturing for the big pharma is also

another major focus area," said Pranav Amin, the eldest son of Chirayu Amin, the chairman and managing director of Alembic.

Alembic has already signed a three-year contract manufacturing agreement with a multinational company to supply APIs, which will fetch it $25-30 million annually.

It also licensed a novel drug delivery system for the extended release version of Keppra (levetiracetam), Belgian drug major UCB's leading epilepsy drug.

Alembic will benefit with milestone payments of $11 million and low to medium single-digit royalties on worldwide sales of the new Keppra product, which will soon enter the market.

Commenting on the domestic market, Pranav Amin said the company has restructured the domestic business, with eight marketing divisions, instead of the earlier five divisions, to focus on acute, chronic and other speciality products.

The domestic marketing team has shifted to Mumbai from Vadodara, the home of Alembic. The company recruited 600 medical representatives alone during the last quarter to have a field force of 2,800.

He said focus in the domestic market will be on creating more brands, especially in acute and speciality segments, to maintain an average growth rate of over 15 per cent every year.

Alembic, the market leader in anti-infective segment (macrolides), has brands such as Azithral (Rs 60-crore sales) Althrocin (Rs 72.5 crore) and Roxid (Rs 62 crore), which help control about 38 per cent of the domestic market for anti-infectives.

The acquisition of Dabur's non-oncology business during the last year has helped add about 23 products to the basket, he said.

Alembic seeks allies in US to double sales

The 101-year-old Alembic, India's oldest pharmaceutical company, has chalked out an aggressive expansion plan to double its turnover within 2 to 3 years by foraying into the regulated markets of the US and Europe as well as contract manufacturing.

The Rs 1,027-crore company has filed 13 abbreviated new drug applications (ANDAs) and 22 drug master files (DMFs) with the US Food and Drug

Administration (FDA) and regulatory agencies in Europe for supply of formulations and active pharmaceutical ingredients (APIs).

Some of the ANDAs challenge innovator patents and the company's strategy will be to partner with established companies in the US and Europe for marketing formulations, said Pranav Amin, director, Alembic.

"I feel we are about ten years late to enter the regulated markets, but will file about 10-12 ANDAs every year to tap potential in the generic markets of the US and Europe. We will also tap Latin America and Africa," he said.

Alembic's plan is to follow the low-risk and less-expensive model of roping in strategic alliances with major companies with presence in the US and Europe for supplying drugs, similar to the business model of drug major Cipla, instead of creating own front-ends through greenfield projects and expensive acquisitions in various geographies.

Currently, exports to non-regulated markets contribute only 20 per cent of the turnover and plans are afoot to improve this to a ratio of 50:50 in coming years. Alembic was talking to several multinational and domestic companies to rope in alliances, he said.

"Now large retail chains in the US are looking at second-level Indian companies with quality manufacturing facilities for direct drug supplies and we will try to capitalise that opportunity. Contract manufacturing for the big pharma is also another major focus area," said Pranav Amin, the eldest son of Chirayu Amin, the chairman and managing director of Alembic.

Alembic has already signed a three-year contract manufacturing agreement with a multinational company to supply APIs, which will fetch it $25-30 million annually.

It also licensed a novel drug delivery system for the extended release version of Keppra (levetiracetam), Belgian drug major UCB's leading epilepsy drug.

Alembic will benefit with milestone payments of $11 million and low to medium single-digit royalties on worldwide sales of the new Keppra product, which will soon enter the market.

Commenting on the domestic market, Pranav Amin said the company has restructured the domestic business, with eight marketing divisions, instead of the earlier five divisions, to focus on acute, chronic and other speciality products.

The domestic marketing team has shifted to Mumbai from Vadodara, the home of Alembic. The company recruited 600 medical representatives alone during the last quarter to have a field force of 2,800.

He said focus in the domestic market will be on creating more brands, especially in acute and speciality segments, to maintain an average growth rate of over 15 per cent every year.

Alembic, the market leader in anti-infective segment (macrolides), has brands such as Azithral (Rs 60-crore sales) Althrocin (Rs 72.5 crore) and Roxid (Rs 62 crore), which help control about 38 per cent of the domestic market for anti-infectives.

Alembic launching 7 new products

Vadodara April 13 The Vadodara-based pharma company Alembic Ltd is set to launch several new products and expects to enter the $200-million formulations spectrum as a future growth strategy in the overseas market in the next couple of years.

The century-old Alembic with a basket of 200 products is now actively eyeing the $200-million spectrum in branded formulations business or API. It is also set to launch seven new products apart from the 24 it recently acquired from Dabur.

Plans are afoot to celebrate Alembic's centenary this year, Chairman and Managing Director, Mr Chirayu Amin, told Business Line here.

Besides, it is putting in place a new marketing strategy of its popular cough syrup Glycodin whose sales have shown a downward trend in the recent past.

Announcing completion of acquisition of the entire non-oncology formulation business of Dabur Pharma Ltd with 24 brands for a consideration of Rs 159 crore, Mr Amin, said that the company may try to reallocate its assets for financing the recent take-over. Alembic Ltd and Alembic Glass own about 130 acres each in Vadodara. "We created debt to finance Rs 159 crore and borrowed money. We have good accruals and we may unlock our assets in a couple of years," he told reporters.

The acquired product mix had a turnover of Rs 75 crore in the last fiscal, which Alembic expects to increase to Rs 100 crore this year and double in the next three to four years.

Alembic, whose turnover was nearly Rs 700 crore also expects to increase it to Rs 1,000 crore next year. "We expect our bottomline from the acquisition to be more than 25 per cent and operating margin Rs 200 crore."

In the next four years, the company expected to equalise its revenue from domestic and foreign sales from the current 75 per cent and 25 per cent, respectively.

Mr Amin pointed out that most brands Alembic acquired from Dabur are in the high growth lifestyle therapeutic segments of cardiology, diabetology and gynaecology. Alembic has created a new marketing arm, named "Summit," to cater to the needs of these speciality segments. It is already the largest player in the Macrolides (anti-infective) segment of drugs and is now set to increase market share in the lifestyle segment as well.

Article: Alembic plans to set up its own SEZ.

Alembic plans to set up its own SEZ

Vadodara, Mar 27 (PTI) Alembic, the oldest pharmaceutical company in the country, has decided to set up its own Special Economic Zone (SEZ) dedicated to the pharma sector, its Chairman and Managing Director Chirayu Amin said today.

The land for the proposed SEZ is located at Kavi and Nahar village on the Mahisagar Tidal sanctuary, about 60 kms from here, Amin told PTI.

This will be a single sector SEZ focussing on meeting the requirments of the pharmaceutical industry for the entire spectrum of naturally Derived/Biologically-developed/ Semi-Synthetically-developed/Synthetically-developed drugs and their ...

Alembic POS goes live!

Max is an old and true friend, and I was delighted to get him set up with a good starter site. 

Max is also a keen geek, so I decided against putting a layer of abstraction, such as a CMS or blogging platform, between him and his code. Instead I tried to build good code. I started with a variation on the Blueprint CSS framework, to reset browser styles to a consistent layout, simplify inner-

page styling, and get that ever-so-elegant vertical alignment, the “je-ne-sais-quoi” that makes a site look incredibly more pleasant and professional. 

The logo is an old friend. It was designed in 1992 by Todd Steigerwald, an amazingly talented designer and illustrator, and close friend to both Max

and me. Max has obtained the rights to this logo for his new venture, and it was a treat to get to work with it. I added a bit of light and shadow to it, but kept even the original typeface, which I think still works. We sure enjoyed

character stretching in the late eighties and early nineties!

In terms of marketing strategy, we went ahead with “local matters”, since that is Alembic’s stronger differentiator for prospects and new clients, until they get to know Max. A picture of Red Rocks national park would click with our target market, and it gave us a warm, vibrant color scheme, miles away

from corporate blue. 

In the end, I’ve given Max a clean base to start from. Thanks to Blueprint, the html code stays very light and very discoverable, perfect for hand-

editing. And the visual design and brand identity should give him an edge on his drab and messy competitio .

Alembic in talks for acquiring domestic ophthalmic company Ophthalmics is a niche segment and unlike other categories in the domestic pharmaceutical market which are crowded.

Mumbai: Alembic Ltd, the maker of the cough preparation Glycodin which acquired part of Dabur’s pharmaceuticals business earlier this year is now eyeing a domestic maker of ophthalmic products as part of its inorganic growth strategy. “We plan to enter the ophthalmic segment through an acquisition in this space and we are in discussions to buy a company. The size of the deal could be about Rs100 crore,” said Chirayu R. Amin, chairman and managing director of Alembic. He declined to divulge further details.

Alembic ended 2006-07 with Rs700 crore in net sales.

The company said its target would have expertise in manufacturing ophthalmic products. “We can build on these technologies to grow our presence in the ophthalmic segment, both in the domestic market as well as in the international markets,” said Pradeep Rane, president-formulations business, Alembic.

Ophthalmics is a niche segment and unlike other categories in the domestic pharmaceutical market which are crowded, few companies such as Allergan India Pvt. Ltd and Cipla Ltd have a significant presence in it.

The domestic ophthalmology market is currently valued at around Rs400 crore and is growing at over 15%.

Alembic said it was also looking at other “high growth” segments. “We are also interested in companies that have a product portfolio focusing on

gynaecology and dermatology,” said Amin. The company has not yet identified companies in these segments and is still scouting for likely targets.

The acquisitions will help Alembic diversify its portfolio; the company currently earns most of its revenue from anti-infective products. Alembic has also announced the signing of an out-licensing deal with Belgian pharmaceutical company, UCB, for proprietary technology it has developed.

Based on this technology, Alembic claims to have developed a once-a-day formulation version of UCB’s anti-epileptic drug Keppra. It will receive milestone payments of $11 million (Rs45.1 crore) and royalty on future worldwide net sales of the product. Keppra had sales of €761 million in 2006. The Alembic stock on Wednesday rose 12.53% to close at Rs65.10 on the Bombay Stock Exchange.

Alembic sets sights on regulated markets

Mr Atul Barman, Vice-President, Alembic Ltd, at a press conference in Mumbai on Wednesday.

MUMBAI, Oct. 16

ALEMBIC Ltd, the Baroda-based pharma company has set its eyes on the international markets, particularly the regulated ones such as the US Europe. The company currently has a small presence in these lucrative markets.

Says Mr Atul Barman, Vice-President, Alembic Ltd, "We are in the preparatory stage as far as the international markets are concerned. The company has identified two plants in Panela, near Baroda primarily for exporting to these markets."

The company has started upgradation and expansion process in these two manufacturing facilities. "We are hoping to get a USFDA (United States Food and Drug Administration) approval by the end of this year," Mr Barman said.

Alembic is also scouting for potential partners in the US and Europe for marketing and distribution of its products. "We are looking at tying up with other companies for marketing and distribution in the generic category," he said.

The company had late last year announced a restructuring exercise in line with recommendations by global consultants, Accenture, to increase operational efficiency, productivity, cost rationalisation and supply-chain management. Subsequently, Alembic formed five business units, the latest one being SynX.

SynX (or Syndrome X) unit will cater to metabolic disorders comprising central obesity, glucose intolerance, hyperlipidemia and high blood pressure. According to Mr Barman, the target for the first 18 months would be around Rs 25 crore.

"Initially we will be having about nine products in this segment with a team of about 150 people. We will also be setting up a call centre for doctors in case they need any samples of the products," he said.

The company also plans to achieve a turnover of Rs 1,800 crore in the next five years and expects to reach a turnover figure of Rs 1,000 crore in two years.

For the year ended March 2002, the company registered net sales of Rs 560 crore and a net profit of Rs 23.5 crore.

Alembic rises on value buying

Alembic has been rising steadily in the recent past on value buying following a slew of new developments in

the company.

From a recent low of Rs 137 touched on 31 March, the Alembic stock has risen 32.51 per cent  to Rs 181.55

on 9 May -- touching a 52-week high of Rs 194 . While the BSE Healthcare Index has risen 1.69 per cent  in

the same period, the 30-share BSE Sensitive Index (Sensex) has lost 3.23 per cent. The average daily

volumes on the Alembic counter have risen to around 5,000 shares from 2,500 shares during this period.

In a most recent development, Alembic entered into a contract research pact with Chiron Corporation, a

research-based pharmaceutical company based in Emeryville, California, USA.

Chiron applies its advanced understanding of the biology of cancer and infectious disease to develop

products from its platforms in proteins, small molecules and vaccines.

Earlier, Alembic said it was targeting a turnover of Rs 25 crore from its recently set up strategic business unit

SynX for the 18-month period. SynX comprises Alembic's cardio and diabetic division, which currently

accounts for Rs 6.5 crore (Rs 65 million) of the company's turnover. Alembic also said that plans are afoot

for launching seven new products under SynX in the next few months. SynX already has a portfolio of nine

products.

SynX caters to patients suffering from a condition called Syndrome X. Syndrome X is a term indicating the

association of glucose intolerance, dyslipidemia, hypertension and insulin resistance. These metabolic

abnormalities are often associated with insulin resistance.

Alembic has already dedicated a 100-member team for the division. Products that have been brought under

this division include nateglinide (Natelide), pioglitazone (Piolem), gliclazide (GLZ, GLZ Plus), glipiside

(Glipy), metformin (Forminal, Forminal SR), alprazolam (Zocam) and vitamins and minerals (Zivinal CD).

Recently, Alembic has launched a fourth generation injectable cephalosporin, Cefepime, under the brand

name of Cepime. Cepime is the only US FDA approved fourth generation cephalosporin, and its spectrum of

activity is far superior to the existing third generation cephalosporin injections like Ceftazidime, Ceftriaxone

and Cefotaxime.

Earlier, Alembic announced that it was launching a massive nationwide campaign to garner a wider reach in

the rural market for its brand Althrocin, the largest antibiotic brand in India [ Images ].

The campaign, which has been branded 'Hot Wheels', is focussing on doctors in interior areas. The

company wants to penetrate into the rural market. Alembic will put up around 250 shows in different parts of

the country, covering some 4,000 doctors. Besides northern states, the campaign will cover Madhya

Pradesh [ Images ], Maharashtra [ Images ], Andhra Pradesh, West Bengal [ Images ], Tamil Nadu and

Gujarat.

Recently, the Gujarat-based company obtained permission from the Drugs Controller General of India to

launch Cefatemet Pivoxil, an advanced antibiotic. It is the first company to launch the drug in India. Alembic

expects to clock sales of Rs 6 crore in the first year since the launch of the drug.

Alembic has also signed an agreement with an Italian pharma company, Euroresearch, to bring the latter's

products to India. The first product from Euroresearch that Alembic is in the process of launching is Gelfix

Pads. It is also exploring the possibility of introducing more products from Euroresearch to the country, and

is studying the product pipeline of the Italian firm in order to expand the scope of the alliance.

Under the recent restructuring exercise, the company also created five major strategic business units. It has

also identified co-marketing through the franchisee route as a key strategy to optimise performance.

The five SBUs -- pharma, speciality, franchisee, generics, and over-the-counter -- will promote specific

products.

In a bid to optimise the strength of its massive field force of over 1,200, the company also plans to float joint

marketing alliances with other companies.

The company has also identified six therapeutic segments -- antibacterials/antibiotics, women's health, pain

management, cough and cold preparations, anti-diabetic and cardiovascular as focus areas.

Alembic has also decided to make Mumbai [ Images ] the new hub for the marketing operations and it will be

operating its specialty and OTC divisions from this office.

In September 2002, Alembic announced that it would launch a novel drug delivery system for Nimesulide

shortly for treating pain. The NDDS has been named as Nimegesic OD and has been developed at the

company's research centre. Nimuleside is a widely used non-steroidal, anti-inflammatory drug and is

indicated for pain, fever and inflammation.

For the third quarter ended 30 December 2002, Alembic registered a 31.9 per cent  rise in net profit to Rs

10.79 crore (Rs 8.18 crore) on a 2.8% fall in sales to Rs 121.49 crore (Rs 125.05 crore).

As on 31 December 2002, the promoters held 58.2 per cent stake in Alembic, while the public and

institutions held 29 per cent and 4.7 per cent, respectively.